
FDA Approves 2 gMG Treatments, AR1001 Slows Decline in Monotherapy Group of POLARIS-AD Trial, Benjamin Greenberg's, MD, MHS, Insights From the 2026 RNDS
Neurology News Network for the week ending November 21st, 2026. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes | Captions are auto-generated and may contain errors.
Below is a transcript of the video.
Welcome to the Neurology News Network, my name is Louie Pasculli and here’s a look at some of the top stories in Neurology.
The FDA has been extremely busy this week, approving two new therapies for adults with acetylcholine receptor antibody-positive generalized myasthenia gravis, further expanding treatment options for this patient population. First, the agency approved gefurulimab, (Klygefa; Alexion) a once-weekly, self-administered subcutaneous therapy that is a complement C5 inhibitor. Its approval was supported by the phase 3 PREVAIL trial, in which patients receiving gefurulimab demonstrated a 4.2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores at week 26, compared with a 2.6-point improvement with placebo.1
The FDA also approved cemdisiran, (Livsayis; Regeneron Pharmaceuticals)which is a the first small interfering RNA, or siRNA, therapy approved for gMG and is administered subcutaneously once every 3 months. The approval was supported by the phase 3 NIMBLE trial, in which patients receiving cemdisiran experienced a 4.5-point improvement in MG-ADL scores at week 24, compared with a 2.2-point improvement with placebo. Improvements were also observed on the Quantitative Myasthenia Gravis scale, with treatment effects emerging as early as 2 weeks after initiation.2
Although both therapies target complement component C5, they use different mechanisms to achieve this effect. Gefurulimab directly binds C5, while cemdisiran uses RNA interference to reduce the liver’s production of C5. Their dosing schedules also offer different options for patients, with weekly administration for gefurulimab compared with quarterly dosing for cemdisiran. Both therapies carry boxed warnings for serious meningococcal infections and require meningococcal vaccination before treatment. Together, these approvals introduce additional complement-targeting options for adults with AChR antibody-positive gMG, including therapies with less frequent subcutaneous dosing schedules.1,2
Switching gears,the global, randomized, double-blind, placebo-controlled phase 3 POLARIS-AD (NCT05531526) trial showed that AR1001 (AriBio) displayed clinical decline by 31% on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) in the prespecified monotherapy population of individuals with early
The data were presented at the
"The CDR-SB finding in the prespecified Monotherapy population and the safety profile are encouraging," Sha said in a statement.1 "The secondary endpoints and biomarker findings warrant further evaluation alongside the Overall population outcome to understand AR1001's therapeutic effects in early Alzheimer's disease."
In other news, The
In METEOROID study, findings showed that satralizumab reduced the risk of relapse by 68% vs placebo (P = .0025), with 87% of treated patients relapse-free at 48 weeks compared with 67% of those on placebo.5,6 In September 2026, the FDA granted priority review to the supplemental biologics license application for satralizumab in MOGAD, with a decision expected by January 10, 2027.6
Greenberg has also long advocated for retiring the term “transverse myelitis” in favor of a more etiology-informed nomenclature for inflammatory myelopathies.8 Following the symposium, Greenberg spoke with NeurologyLive® to share the key themes from this year’s RNDS and clinical trials clinicians should watch out for in the future. In the conversation, he also talked about how proposed updates to myelitis diagnostic criteria and nomenclature may reshape care, and the unmet needs, including mental health support, that patients raised at the meeting.
To read the full piece and to get more direct access to expert insight, head to NeurologyLive.com. Be sure to tune in next week to remain informed on the latest in neurology. I’m Louie Pasculli, thanks for watching Neurology News Network.
REFERENCES
1. KLYGEFA™ (gefurulimab-gaks) approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients. News release. Alexion, AstraZeneca Rare Disease. Published November 16, 2026. Accessed November 17, 2026. https://www.astrazeneca-us.com/media/press-releases/2026/KLYGEFA-gefurulimab-gaks-approved-in-the-US-for-the-treatment-of-generalized-myasthenia-gravis-gMG-in-adult-patients.html
2. Livsayis™ (cemdisiran) approved by the FDA as first and only siRNA therapy in generalized myasthenia gravis and only treatment with four-times-a-year subcutaneous dosing. News release. Regeneron Pharmaceuticals, Inc. Published November 18, 2026. Accessed November 18, 2026. https://investor.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy
3. AriBio Co., Ltd. AriBio's oral AR1001 meets primary efficacy objective in prespecified monotherapy population in phase 3 POLARIS-AD trial. News release. GlobeNewswire. November 16, 2026. Accessed November 17, 2026. https://www.globenewswire.com/news-release/2026/11/17/3404242/0/en/aribio-s-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-population-in-phase-3-polaris-ad-trial.html
4. 2026 Rare Neuroimmune Disorders Symposium resource center. Siegel Rare Neuroimmune Association. Accessed November 13, 2026. https://wearesrna.org/resources/2026-rnds
5. Levy M, et al. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial. Presented at: 2026 AAN Annual Meeting; April 18-22; Chicago, Illinois.
6. U.S. FDA grants priority review for Roche's enspryng for MOGAD, an autoimmune disease with no approved treatments. News release. Roche. September 9, 2026. Accessed November 13, 2026. https://www.roche.com/media/releases/med-cor-2026-09-10
7. Q study updates: expanded inclusion criteria and what’s next. Siegel Rare Neuroimmune Association. May 18, 2026. Accessed November 13, 2026. https://wearesrna.org/?p=79285
8. Blackburn KM, Greenberg BM. Revisiting Transverse Myelitis: Moving Toward a New Nomenclature. Front Neurol. 2020;11:519468. Published 2020 Sep 23. doi:10.3389/fneur.2020.519468
Related to this article








